BioCentury | Jun 6, 2020
Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

Targeted delivery of antibacterial toxins  University of Washington researchers have co-opted a bacterial secretion system to enable killing of select bacterial species. They d escribed in Cell Host & Microbe how they programmed bacteria with...
BioCentury | Oct 13, 2018
Product Development

Trevena goes for MOR than morphine

FDA’s Anesthetic and Analgesic Drug Products Advisory Committee meeting on pain candidate oliceridine from Trevena Inc. gave the agency little reason to reverse its skepticism about the molecule’s benefits and risks. But it did leave...
BC Extra | Feb 16, 2018
Preclinical News

Improved dopamine receptor agonists for Parkinson’s

A study published in Nature Communications showed that non-catechol dopamine D1 receptor agonists reduced receptor desensitization, suggesting the compounds could help treat Parkinson's disease better than available dopamine replacement therapies. Marketed D1 receptor selective agonists...
BC Extra | Jan 9, 2018
Preclinical News

Selective kappa opioid receptor agonist could dial out side effects

In a study published in Cell , researchers at the University of North Carolina at Chapel Hill and colleagues solved the crystal structure of the kappa opioid receptor (KOR; OPRK1) bound to an opioid agonist and...
BC Innovations | Nov 15, 2016
Distillery Techniques


TECHNOLOGY: Tool compounds Aripiprazole-based biased agonists at the dopamine D2 receptor that activate GNAI1 but not arrestin beta 2 (ARRB2) could be useful as probes for D2 receptor-induced GNAI1 signaling in psychiatric and neurodegenerative diseases....
BioCentury | Aug 10, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 8/7 cls Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) Piper Jaffray Charles Duncan Downgrade Neutral (from overweight) -20% $39.14 Duncan downgraded, saying he...
BioCentury | Oct 28, 2013

Hoping to give thanks

While buysiders suggest the overall quality of the IPO queue has declined, they still see enough diamonds in the rough and expect sufficient generalist-led appetite for deals to keep the window propped open to the...
BC Extra | Oct 9, 2013
Financial News

Trevena jumps in IPO queue

Trevena Inc. (King of Prussia, Pa.) filed to raise up to $86.3 million in an IPO underwritten by Barclays; Jefferies; Canaccord; JMP Securities; and Needham. Trevena is developing GPCR ligands that activate or block specific...
BioCentury | May 13, 2013
Product Development

An association for dissociation

Forest Laboratories Inc. 's investment and option deal with Trevena Inc. last week will support the translation of a successful mechanism for treating chronic heart failure into the acute setting, as well as the development...
Items per page:
1 - 9 of 9